All In Biotech

Drug Trial Radar · NCT05936489

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Last checked: Nov 20, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 6, 2023

Primary completion

Oct 3, 2023

Study completion Oct 3, 2023

Sponsor

Lead sponsor
LENZ Therapeutics, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ORA, Inc.
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.

Conditions

  • Eye Diseases
  • Presbyopia
  • Refractive Errors
  • Brimonidine Tartrate
  • Aceclidine
  • Ophthalmic Solutions

Interventions

  • Aceclidine + BrimonidineDrug

    LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution

  • AceclidineDrug

    LNZ100 (Aceclidine) non-preserved ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Day 1 and Day 8
  2. TmaxTime frame: Day 1 and Day 8
  3. AUC0-tTime frame: Day 1 and Day 8
  4. AUC0-infTime frame: Day 1 and Day 8
  5. T1/2Time frame: Day 1 and Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site #101

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.